Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Conatus Pharmaceuticals Inc (NASDAQ:CNAT)

2.10
Delayed Data
As of 4:14pm ET
 -0.01 / -0.47%
Today’s Change
1.40
Today|||52-Week Range
5.44
-27.08%
Year-to-Date
5 Biotech Stocks to Watch as Interest in NASH Increases
Sep 22 / Zacks.com - Paid Partner Content
Here's Why Conatus Pharmaceuticals (CNAT) Stock Is Soaring Today
Sep 20 / TheStreet.com - Paid Partner Content
Biotech ETFs in Focus on Tobira Therapeutics' Massive Gain
Sep 21 / Zacks.com - Paid Partner Content
These Biotech Names Are on My Radar
Sep 20 / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close2.11
Today’s open2.11
Day’s range1.95 - 2.11
Volume1,149,526
Average volume (3 months)335,066
Market cap$46.6M
Dividend yield--
Data as of 4:14pm ET, 09/26/2016

Growth & Valuation

Earnings growth (last year)+9.72%
Earnings growth (this year)-3.33%
Earnings growth (next 5 years)+74.00%
Revenue growth (last year)--
P/E ratioNM
Price/Sales--
Price/Book1.21

Competitors

 Today’s
change
Today’s
% change
PRANPrana Biotechnology ...-0.04-0.80%
MTEXMannatech Inc-0.21-1.16%
MRNSMarinus Pharmaceutic...-0.04-1.80%
NVETNexvet Biopharma plc-0.09-2.08%
Data as of 3:59pm ET, 09/26/2016

Financials

Next reporting dateNovember 9, 2016
EPS forecast (this quarter)-$0.34
Annual revenue (last year)$0.00
Annual profit (last year)-$24.1M
Net profit margin--

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Steven J. Mento
Chief Financial Officer, Secretary &
SVP-Finance
Charles J. Cashion
Corporate headquarters
San Diego, California

Forecasts

Search for Jobs